<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356118</url>
  </required_header>
  <id_info>
    <org_study_id>BH 005</org_study_id>
    <nct_id>NCT04356118</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis</brief_title>
  <official_title>Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui Bu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the clinical effect and safety of Recombinant Human
      Endostatin in non-small cell lung cancer with leptomeningeal metastasis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leptomeningeal Metastasis Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>Leptomeningeal Metastasis Overall survival defined as time from LM diagnosis to death due to any cause or last follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Progression Free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>From the start of treatment until central nervous system metastase progression or death due to any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of adverse reactions</measure>
    <time_frame>36 months</time_frame>
    <description>From date of first dose up to assessed from April 2020 to April 2023 (In accordance with the standard of CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>ORR, proportion of patients with a best overall response of complete response or partial response (CR+PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological assessment</measure>
    <time_frame>36 months</time_frame>
    <description>In accordance with the standard of Response Assessment in Neuro-Oncology(RANO) Neurological Assessment group.The maximum value is 29 and the minimum value is 0.The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>36 months</time_frame>
    <description>Proportion of patients progression-free by investigator assessment per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>defined as time from Non-Small Cell Lung Cancer diagnosis to death due to any cause or last follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <arm_group>
    <arm_group_label>Endostatin Therapy for NSCLC of LM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer
Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.
intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.
Targeted drugs for non-small cell lung cancer:
EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Endostatin</intervention_name>
    <description>endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.</description>
    <arm_group_label>Endostatin Therapy for NSCLC of LM</arm_group_label>
    <other_name>Endostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathcal methotrexate</intervention_name>
    <description>Intrathecal chemotherapy specified dose on specified days.</description>
    <arm_group_label>Endostatin Therapy for NSCLC of LM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted drugs for non-small cell lung cancer</intervention_name>
    <description>EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .</description>
    <arm_group_label>Endostatin Therapy for NSCLC of LM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 18 years old

          2. Pathologically proven non-small cell lung cancer

          3. Karnofsky performance status ≥ 40

          4. LM diagnosis was based on the detection of malignant cells in the CSF, the focal or
             diffuse enhancement of leptomeninges, and nerve roots or the ependymal surface on
             gadolinium-enhanced MRI .

          5. No severe abnormal liver and kidney function;

          6. Patients have the ability to understand and the willingness to sign a written informed
             consent document.

        Exclusion Criteria:

          1. Evidence of bleeding diathesis or serious infection

          2. Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,
             unstable angina, myocardial infarction, serious heart valve disease, resistant
             hypertension)

          3. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Bu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Bu</last_name>
    <phone>86-13831106903</phone>
    <email>buhuimy1@163.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>May 23, 2020</last_update_submitted>
  <last_update_submitted_qc>May 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Hui Bu</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Recombinant Human Endostatin</keyword>
  <keyword>Non-Small Cell Lung Cancer with Leptomeningeal Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

